論文 - 詳細
| RRC ID | 76992 |
|---|---|
| 著者 | Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, Denoyelle C, Villenet C, Sebda S, Briand M, Joly F, Dolivet E, Goux D, Blanc-Fournier C, Jeanne C, Villedieu M, Meryet-Figuiere M, Figeac M, Poulain L, Weiswald LB. |
| タイトル | Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. |
| ジャーナル | J Exp Clin Cancer Res |
| Abstract |
BACKGROUND:In the era of personalized medicine, the establishment of preclinical models of cancer that faithfully recapitulate original tumors is essential to potentially guide clinical decisions. METHODS:We established 7 models [4 cell lines, 2 Patient-Derived Tumor Organoids (PDTO) and 1 Patient-Derived Xenograft (PDX)], all derived from the same Ovarian Clear Cell Carcinoma (OCCC). To determine the relevance of each of these models, comprehensive characterization was performed based on morphological, histological, and transcriptomic analyses as well as on the evaluation of their response to the treatments received by the patient. These results were compared to the clinical data. RESULTS:Only the PDX and PDTO models derived from the patient tumor were able to recapitulate the patient tumor heterogeneity. The patient was refractory to carboplatin, doxorubicin and gemcitabine, while tumor cell lines were sensitive to these treatments. In contrast, PDX and PDTO models displayed resistance to the 3 drugs. The transcriptomic analysis was consistent with these results since the models recapitulating faithfully the clinical response grouped together away from the other classical 2D cell culture models. We next investigated the potential of drugs that have not been used in the patient clinical management and we identified the HDAC inhibitor belinostat as a potential effective treatment based on PDTO response. CONCLUSIONS:PDX and PDTO appear to be the most relevant models, but only PDTO seem to present all the necessary prerequisites for predictive purposes and could constitute relevant tools for therapeutic decision support in the context of these particularly aggressive cancers refractory to conventional treatments. |
| 巻・号 | 42(1) |
| ページ | 260 |
| 公開日 | 2023-10-7 |
| DOI | 10.1186/s13046-023-02809-8 |
| PII | 10.1186/s13046-023-02809-8 |
| PMID | 37803448 |
| PMC | PMC10559504 |
| MeSH | Carcinoma* Cell Line, Tumor Humans Organoids* Treatment Outcome Xenograft Model Antitumor Assays |
| IF | 7.068 |
| リソース情報 | |
| ヒト・動物細胞 | JHOC-5(RCB1520) |